
    
      Patients who are scheduled for craniotomy and tumor resection will receive one dose of
      veledimex before the resection procedure. Ad-RTS-hIL-12 will be administered by free-hand
      injection. Patients will continue on oral veledimex for 14 days.

      The study is divided into three periods: the screening period, the treatment period and the
      follow-up period.
    
  